Table 3.
Pharmacokinetic parameters of AmB formulations
| AmB equivalent concentration in formulation | Cmax (ng·mL−1) | AUC0–48 (h × ng·mL−1) | CL (mL·h−1·kg−1) | MRT (h) | t1/2 (h) |
|---|---|---|---|---|---|
| AmB (10 mg·kg−1) | 297.2 ± 47.4 | 4 102.7 ± 889.3 | 2525.7 ± 647.5 | 11.0 ± 2.4 | 5.9 ± 0.9 |
| CopNEC-AmB (5 mg·kg−1) | 1213.1 ± 109.8 | 23 868.1 ± 2 183.6 | 388.4 ± 34.4 | 19.7 ± 3.1 | 14.6 ± 2.4 |
| CopNEC-AmB (10 mg·kg−1) | 2139.9 ± 127.2 | 43 222.7 ± 6 537.8 | 207.4 ± 30.6 | 22.0 ± 3.7 | 15.9 ± 1.7 |
Each result represents the mean ± SD (n = 3). AmB, amphotericin B; CL, clearance; Cop, copaiba oil; MRT, mean residence time; NEC, nanoemulsified carrier.